Zydus Lifesciences Ltd

Announcement under Regulation 30 (LODR)-Press Release / Media Release

12:21 PM, 6th Feb 2026

Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease.